Merck & Co. is forecast to recover from underperformance in 2025 thanks to multiple late‐stage developments and commercial initiatives. The company reported positive phase II data for its inhaled RSV therapy Winrevair, showing a 60% reduction in hospitalization risk in patients over 65, and announced a planned regulatory filing for its CD388 bispecific antibody in indolent non‐Hodgkin lymphoma by mid‐2026. On the commercial front, the recent launch of its subcutaneous Keytruda formulation has already captured 15% share in first‐line non‐small cell lung cancer markets within three months. Management expects these catalysts to offset the 2028 patent expiration on its blockbuster oncology franchise.

Merck recently suspended acquisition discussions with clinical‐stage biotech Revolution Medicines after failing to agree on a buyout price reported to be near $30 billion. According to sources, Merck maintained strict valuation discipline despite interest in Revolution’s Phase 3 RAS inhibitor daraxonrasib, now enrolling 200 pancreatic cancer patients. While the Wall Street Journal indicated that negotiations could resume, Merck has also drawn interest from other prospective acquirers such as AbbVie, underscoring its continued focus on high-growth oncology assets without overpaying.